| Literature DB >> 34625047 |
H Murua Escobar1,2, I Nolte3, F Weiner4,1, J T Schille4,1, D Koczan5, X-F Wu6, M Beller6, C Junghanss1, M Hewicker-Trautwein7.
Abstract
BACKGROUND: The aminoisoquinoline FX-9 shows pro-apoptotic and antimitotic effects against lymphoblastic leukemia cells and prostate adenocarcinoma cells. In contrast, decreased cytotoxic effects against non-neoplastic blood cells, chondrocytes, and fibroblasts were observed. However, the actual FX-9 molecular mode of action is currently not fully understood.Entities:
Keywords: Antimitotic agent; G1-phase arrest; Isoquinolinamine FX-9; Microarray analysis; NF-κB signaling; Prostate cancer
Mesh:
Substances:
Year: 2021 PMID: 34625047 PMCID: PMC8501574 DOI: 10.1186/s12885-021-08836-y
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1A: PCA mapping: Three-dimensional diagram: clear differentiation of the three sample groups showing high consistency within the individual replicates in the original dataset. B: Venn diagram: Number of DEGs in 6-h and 12-h samples are displayed and overlapping DEGs (n = 53) are highlighted in purple. C and D: Volcano plots after 6-h and 12-h exposure of 5 μM FX-9. Plots display the FC against the negative decadic logarithm of the FDR-value. Color code: red FC > 2, green FC < − 2, both with LIMMA p-value < 0.05, and FDR-value < 0.05
Reactome top 15 enriched signaling pathways after 6-h exposure of FX-9
| No. | Super-pathway | Signaling Pathway | DEGs | Entities | |
|---|---|---|---|---|---|
| found | FDR | ||||
| 1 | IS | Interleukin-4 and Interleukin-13 signaling | 8 | 17/216 | 2.24e-05 |
| 2 | MR | Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | 2 | 6/13 | 2.24e-05 |
| 3 | IS | Interleukin-10 signaling | 5 | 11/86 | 2.73e-05 |
| 4 | IS | Signaling by Interleukins | 17 | 29/647 | 4.07e-05 |
| 5 | IS | Cytokine Signaling in Immune system | 26 | 37/1108 | 7.63e-04 |
| 6 | GE | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 2 | 5/20 | 0.002 |
| 7 | ST | Antagonism of Activin by Follistatin | 3 | 3/4 | 0.003 |
| 8 | ST | Signaling by TGFB family members | 7 | 9/114 | 0.006 |
| 9 | CC | Transcriptional activation of cell cycle inhibitor p21 | 1 | 3/6 | 0.008 |
| 10 | CC | Transcriptional activation of p53 responsive genes | 1 | 3/6 | 0.008 |
| 11 | IS | CLEC7A/inflammasome pathway | 1 | 3/8 | 0.015 |
| 12 | IS | Interleukin-1 processing | 2 | 3/8 | 0.015 |
| 13 | CR | Cellular Senescence | 7 | 11/200 | 0.015 |
| 14 | IS | NOD1/2 Signaling Pathway | 5 | 5/40 | 0.02 |
| 15 | IS | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 6 | 6/70 | 0.035 |
Superpathways: IS “immune system”, MR “metabolism of RNA”, GE “gene expression (RNA polymerase II transcription)”, CC “cell cycle”, ST “signal transduction”, and CR “cellular response to external stimuli”. The found entities display the number of entries of the DEGs in the signaling pathway.
Fig. 2DEGs belonging to Reactome pathways “Immune System”, and “Cell Cycle” after 6-h and 12-h FX-9 exposure. Numbers given for each gene display the FC (in linear space) of 6-h and 12-h samples versus the control. Values highlighted in red or blue indicate significantly higher or lower expression. Non-highlighted values are not significantly different (LIMMA p-value < 0.05, and FDR-value < 0.05)
Reactome top 15 enriched signaling pathways after 12-h exposure of FX-9
| No. | Super-pathway | Signaling Pathway | DEGs | Entities | |
|---|---|---|---|---|---|
| found | FDR | ||||
| 1 | GE | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 6 | 9/20 | 8.77e-09 |
| 2 | CR | Cellular Senescence | 14 | 17/200 | 8.10e-07 |
| 3 | CR | DNA Damage/Telomere Stress Induced Senescence | 10 | 11/71 | 1.06e-06 |
| 4 | CC | Mitotic G1 phase and G1/S transition | 10 | 15/173 | 2.85e-06 |
| 5 | GE | TP53 Regulates Transcription of Cell Cycle Genes | 7 | 10/65 | 3.46e-06 |
| 6 | CC | Cell Cycle | 22 | 30/734 | 5.34e-06 |
| 7 | CC | Cell Cycle Checkpoints | 14 | 18/280 | 5.34e-06 |
| 8 | CC | Cell Cycle, Mitotic | 19 | 25/596 | 3.98e-05 |
| 9 | CR | Senescence-Associated Secretory Phenotype (SASP) | 9 | 10/91 | 4.00e-05 |
| 10 | R | DNA Replication | 10 | 12/142 | 4.00e-05 |
| 11 | DB | Transcriptional regulation of granulopoiesis | 10 | 9/71 | 4.00e-05 |
| 12 | CC | Deposition of new CENPA-containing nucleosomes at the centromere | 8 | 8/54 | 4.56e-05 |
| 13 | CC | Nucleosome assembly | 8 | 8/54 | 4.56e-05 |
| 14 | CC | G1/S Transition | 10 | 12/150 | 5.11e-05 |
| 15 | MR | Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | 1 | 5/13 | 5.11e-05 |
Superpathways: GE “gene expression (RNA polymerase II transcription)”, CR “cellular response to external stimuli”, CC “cell cycle”, R “DNA replication”, DB “developmental biology”, and MR “metabolism of RNA”. The found entities display the number of entries of the DEGs in the signaling pathway.
DAVID analysis functional annotation, gene ontology, 6-h and 12-h FX-9 exposure
| GO.biological processes | 6-h | 12-h | ||
|---|---|---|---|---|
| DEGs | FDR | DEGs | FDR | |
| inflammatory response | 18 | 1.30E-04 | 12 | 2.70E-02 |
| angiogenesis | 14 | 1.30E-04 | 13 | 1.70E-04 |
| positive regulation of cell migration | 12 | 4.80E-04 | 11 | 6.00E-04 |
| positive regulation of angiogenesis | 10 | 4.80E-04 | 9 | 8.40E-04 |
| I-kappaB kinase/NF-kappaB signaling | 7 | 5.30E-03 | ||
| negative regulation of cell proliferation | 15 | 5.30E-03 | ||
| positive regulation of NF-kappaB transcription factor activity | 9 | 7.40E-03 | ||
| positive regulation of transcription from RNA polymerase II promoter | 24 | 8.00E-03 | ||
| extracellular matrix organization | 10 | 1.40E-02 | 10 | 4.80E-03 |
| negative regulation of apoptotic process | 15 | 1.40E-02 | 14 | 9.40E-03 |
| cell adhesion | 15 | 1.40E-02 | ||
| positive regulation of nitric-oxide synthase biosynthetic process | 4 | 2.50E-02 | ||
| positive regulation of ERK1 and ERK2 cascade | 9 | 2.70E-02 | ||
| G1/S transition of mitotic cell cycle | 9 | 6.00E-04 | ||
| positive regulation of endothelial cell proliferation | 6 | 2.70E-02 | ||
ICC-staining comparing control cells with cells after 12-h or 24-h exposure to 5 μM FX-9
| 12-h | 24-h | ||||
|---|---|---|---|---|---|
| control | 5 μM FX-9 | control | 5 μM FX-9 | ||
| CDKN1A (p21) | intensity | m | w-m | m | m |
| positively stained cells | + | + | ++ | +++ | |
| E2F1 | intensity | w-m | m | w-m | w-m |
| positively stained cells | +++ | +++ | ++ | ++ | |
| SERPINE1 (PAI-1) | intensity | w | w | w | w |
| positively stained cells | +++ | ++++ | ++++ | ++++ | |
| NFKB2 | intensity | m-s | s | w-m | m-s |
| positively stained cells | ++++ | ++++ | ++++ | ++++ | |
Intensity of ICC-staining is categorized into negative (n); weak (w); moderate (m); strong (s). The fraction of positively stained cells are categorized into four groups: + = 0–10% of labeled cells; ++ = 11–40% of labeled cells; +++ = 41–70% of labeled cells; ++++ = 71–100% of labeled cells. Images of ICC-stainings are included into supplementary information (supplementary Figs. 1 and 2).